NFXF Blog
Featured
Our 2026 NFXF awards are in! Learn more about each award and the respective awardees.
FXS Tips & Support for Traveling + Free Downloads
06 mins read
Two Letters for Parents With a New Fragile X Syndrome Diagnosis
04 mins read
Watch the 2026 NFXF Summer Scholars Award Recipients’ Research Project Presentations
01 hour 00 min read
Symposium Summary: Prenatal and Newborn Screening in Fragile X Syndrome
05 mins read
All Articles
[This is an archived page referring to the Seaside Arbaclofen (STX209) clinical trial, which was terminated in 2013.] We have experienced a setback with the cancellation of the extension phase of the STX209 drug trials for Fragile X syndrome, and what have been deemed the technical failures of two other ongoing trials of this drug.
[This is an archived page referring to the Seaside Arbaclofen (STX209) clinical trial, which was terminated in 2013.] By now, many of you have heard that Seaside Therapeutics has decided to end the extension of the trial medication Arbaclofen (STX209).